



streamline HEALTH[®]

Third Quarter 2022 Earnings Presentation

Nasdaq: STRM

Disclosure Statement

SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE

This presentation contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, based on current management expectations. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and that can cause Streamline Health’s actual results to differ. We caution you therefore to not place undue reliance on such statements.


Actual results might differ materially from these statements due to a number of risks and uncertainties. Risks that may contribute to the uncertain nature of these statements are described in Streamline Health’s periodic filings made with Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Streamline Health undertakes no obligation to update any forward-looking statements or relevant risks, except as may be required by law.

TRADEMARKS

Product or company names referenced herein may be trademarks or registered trademarks of their respective owners

Third Quarter & Recent Highlights

Booked SaaS ACV



Significant growth of Booked SaaS ACV throughout Fiscal 2022, anticipate achievement of \$17M of Booked SaaS ACV by end of the fiscal year

\$14.1M

TCV SaaS Bookings as of 10/31/22

Strengthened balance sheet through **\$8.3M** offering, recent operational alignment accelerate growth and yields more efficient cost structure

Operations Update

Innovation

- Primary focus on improvements to Avelead suite back-end architecture
- Working to implement features that drive value for clients into Avelead suite, similar to eValuator dashboard and reporting tools
- Improvements to Avelead architecture should reduce effort associated with implementation for RevID, Compare
- Continuing to make incremental improvements to eValuator, expanding ruleset and creating a more effective solution

Service

- Client success remains key differentiator for eValuator
- Expanding recently announced eValuator concierge to assist clients with staffing challenges
- Staffing within hospital IT departments presents a challenge for implementation timing, working to ensure we are never the bottleneck

Growth

- Maintaining 4-region structure
- Expanded infrastructure to include strong sales enablement and stronger marketing function
- Updated branding and expanding thought leadership presence

Maintain **\$17M** Booked SaaS ACV goal by end of Fiscal 2022

Financial Results

	Third Quarter 2022 Three Months Ended October 31, 2022	Third Quarter 2021 Three Months Ended October 31, 2021	Nine Months Ended October 31, 2022	Nine Months Ended October 31, 2021
Revenue	\$6.2M	\$5.5M	\$18.1M	\$11.3M
Operating Expenses <i>(including transaction costs)</i>	\$9.4M	\$9.3M	\$27.1M	\$20.0M
Loss From Continuing Operations <i>(including transaction costs and forgiveness of PPP Loan)</i>	(\$3.1M)	(\$4.4M)	(\$9.2M)	(\$6.9M)
Net Loss	(\$3.1M)	(\$4.3M)	(\$9.2M)	(\$6.5M)
Adj. EBITDA	(\$1.2M)	(\$0.3M)	(\$3.6M)	(\$1.7M)

Streamline Health defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. Please see the appendix for a reconciliation of non-GAAP Adjusted EBITDA to GAAP Net Income.

Clean Capital Structure

Cash & cash equivalents (As of 10/31/22)	\$11.7M
Debt (as of 10/31/22)	\$9.8M 5-year term loan with favorable repayment terms <i>(new \$2m revolving credit facility after the quarter)</i>
Common Stock (as of 12/12/22)	57.4M shares outstanding


Looking Forward

■ Maintain Focus on Growth of SaaS Revenue

Booked SaaS ACV of \$15.9M as of 11/30/22, \$4.5M unimplemented

■ Break Even

We believe overall business achieves breakeven at \$17M of installed SaaS ACV; anticipate achieving \$17M of Booked SaaS ACV during 4Q22, and implementing by Fiscal 3Q or 4Q of 2023





streamline HEALTH[®]

Third Quarter 2022 Earnings Presentation

Nasdaq: STRM

Reconciliation of Adjusted EBITDA to Net income (000's)

	Three Months Ended		Nine Months Ended	
	October 31, 2022	October 31, 2021	October 31, 2022	October 31, 2021
Loss from continuing operations	\$ (3,138)	\$ (4,379)	\$ (9,197)	\$ (6,913)
Interest expense	198	85	519	107
Income tax expense	9	4	22	9
Depreciation	13	16	40	53
Amortization of capitalized software development costs	446	446	1,293	1,430
Amortization of intangible assets	463	490	1,519	721
Amortization of other costs	131	110	360	338
EBITDA	\$ (1,878)	\$ (3,228)	\$ (5,444)	\$ (4,255)
Share-based compensation expense	555	537	1,212	1,659
Non-cash valuation adjustments	(163)	417	(188)	417
Acquisition-related costs, severance and transaction-related bonus	387	1,953	1,010	2,730
Forgiveness of PPP Loan and accrued interest	-	-	-	(2,327)
Other non-recurring charges	(73)	-	(140)	16
Loss on early extinguishment of debt	-	43	-	43
Adjusted EBITDA	\$ (1,172)	\$ (278)	\$ (3,550)	\$ (1,717)